Optimi Health Achieves 6% Psilocybin Purity, Boosting Australia Supply and EU Trials
OPTH•Optimi Health completed a production run of naturally derived psilocybin extract with 6% psilocybin content, its highest-purity extract to date. Part of the extract will fuel European clinical trials and bolster supply of 5 mg capsules for Australian treatment-resistant depression patients, with no serious adverse events reported through December 2025.
1. Production Milestone
Optimi Health has completed a production run yielding naturally derived psilocybin extract with approximately 6% psilocybin content, marking the highest-purity botanical extract in the company’s commercial history.
2. European Clinical Supply
A portion of the 6% extract has been allocated to upcoming sponsor-led clinical research programs in Europe, where Optimi will supply GMP-grade finished psilocybin material for mental health studies.
3. Australian Treatment Provision
The higher-purity extract strengthens the company’s supply of 5 mg psilocybin capsules prescribed under Australia’s Authorized Prescriber Scheme for treatment-resistant depression, with no serious adverse events reported through December 2025.
4. Cultivation and Extraction Platform
Optimi’s proprietary library of over 200 mushroom genetics, along with refined cultivars and enhanced extraction processes, has driven sustained gains in psilocybin concentration while preserving a naturally derived profile at scale.
